Kornimate/medical-research-clean huggingface dataset:
using peers to promote exercise in older adults

Conditions: Cardiovascular Diseases

Summary: a randomized controlled trial to evaluate the effects of a 12-month telephone-supervised, home-based physical activity intervention, delivered via health educators versus supervised, trained peers, on physical activity patterns. inactive men and women ages 50 years and older will be randomly assigned to one of these two programs or to an attention-control arm.

background: despite the recognized benefits of regular physical activity, older adults remain among the most inactive segments of the u.s. population. a number of studies have demonstrated the health impact and resultant reduction in chronic disease risk achieved by improving physical activity patterns. effective telephone-based counseling approaches for promoting and sustaining regular physical activity among older adults have been developed and validated. such mediated interventions provide a level of individual tailoring and ongoing support to long-term adherence, while allowing for ongoing program delivery that is more flexible, convenient, and potentially lower-cost than face-to face program delivery formats. telephone-based delivery format also allows for potentially greater reach into segments of the older population that may find it difficult or unappealing to come to community settings on a regular basis. design narrative: a 12-month randomized trial in which women and men ages 50 years and above living in the san francisco bay area who meet medical and physical activity criteria, following a baseline evaluation, be randomized to one of three study arms: telephone-supervised, home-based physical activity instruction via a trained health educator; telephone-supervised, home-based physical activity instruction via a supervised peer facilitator; or an attention-control arm consisting of health educator-based telephone delivery of non-physical activity oriented health information and support. all subjects will have a follow-up evaluation at 6 and 12 months.

Eligibility criteria:
women and men ages 50 years and above of the san francisco bay area who are free of any medical condition or disorder that would limit participation in moderate intensity exercise, not hypertensive, stable on all medications, possess english-speaking and reading skills, and are available and able to participate in the evaluations and intervention.
efficacy and safety evaluation of hyperthermic baths in the treatment of seizures in children with cdkl5 deficiency

Conditions: CDKL5 Deficiency Disorder

Summary: the primary objective of this research is to study the efficacy and safety of hyperthermic baths as adjunctive therapy for reducing the frequency of seizures in cdkl5 deficiency.

this project aims to include 8 participants, and evaluate the effectiveness and safety of hyperthermic baths in patients with cdkl5 deficiency through a single-center, preliminary feasibility clinical trial. it is expected to provide new therapeutic options for patients with cdkl5 deficiency with alternative treatment options.

Eligibility criteria:
inclusion criteria: * a diagnosis of cdkl5 deficiency, including molecular confirmation of a pathogenic or likely pathogenic cdkl5 variant and refractory seizures * male or female participants aged 6 months to less than 6 years * parent(s) or lar willing to give written informed consent, after being properly informed of the nature and risks of the study and prior to engaging in any study-related procedures * failure to control seizures despite appropriate trial of 1 or more anti-seizure medications at therapeutic doses * have a history of at least 16 countable seizures per 4 weeks during the 8 weeks prior to screening. countable seizures will be defined by the following:seizures with or without impairment of consciousness with a clear motor component, including generalized tonic-clonic, focal to bilateral tonic-clonic, atonic, bilateral clonic, bilateral tonic, focal motor seizures with or without impaired awareness, or infantile spasms. clusters of infantile spasms/tonic seizures will be counted as a single seizure. * participants should be on a stable regimen of anti-seizure medications for ≥ 4 weeks prior to the screening visit, without a foreseeable change in dosing for the duration of the db phase. * vagus nerve stimulator (vns) are permitted, but should be implanted for 1 year prior to screening and settings should be unchanged throughout the study. * parent/caregiver is able and willing to maintain an accurate and complete daily seizure ediary for the duration of the study. exclusion criteria: * any history of previous brain disease (trauma, etc.) that likely to precipitate seizures. * tissue damage (eczema, etc.) in the area where hyperthermic baths will be applied on the skin. * seizures associated with hyperthermic baths. * presence of any clinical condition that in the opinion of the principal investigator makes the patient not suitable to participate in the trial.

Keywords: hyperthermic baths drug resistant epilepsy cdkl5
effects of goal-directed fluid therapy on post-operative outcomes in children undergoing scoliosis repair

Conditions: Scoliosis; Acute Kidney Injury

Summary: surgery for scoliosis correction, the abnormal curvature of the spine, is a major procedure often undertaken in adolescents. in adult anesthesia, there is a large volume of literature debating how to optimize fluids administered during surgery, as both too much fluid and too little fluid are associated with worse outcomes. the investigators will compare fluid administration based on the measured amount of blood pumped by the heart during each heart beat (goal-directed therapy), against standard anesthetic management. the main outcomes are a) post-surgical kidney dysfunction, b) prevalence of intraoperative hypotension, c) volumes of administered fluids, and d) length of hospitalization.

1. written informed consent from parent/guardian and assent from the patient will be obtained. 2. each patient will be randomized into either the control arm or cardio q directed fluid therapy arm. 3. the following standard monitors will be placed before induction of anesthesia: electrocardiography, non-invasive blood pressure and pulse oximetry. the patient is anesthetized in the supine position using a standardized anesthetic technique. all attempts will be made to maintain normothermia 4. following induction of anesthesia, the following will be placed: invasive arterial cannula, large bore intravenous cannula, bispectral index monitor, temperature probe and central venous cannula (if needed). 5. cardiac output monitor: following induction of anesthesia and after placement of appropriate lines and monitors, a transoesophageal doppler (ted) probe will be inserted through the mouth into the esophagus and positioned correctly. a normal saline infusion will be started once the patient is anesthetized at 0.5 ml/kg/hour in the line where the drugs will be infused. 1. control group: in this group, fluid administration, using boluses of 5ml/kg of plasmalyte at the anesthesiologist's discretion will be used. anesthesiologists will be blinded to the cardio-q numerics on the monitor. the flow waveform and sound will be available to optimize probe position. 2. intervention groups: boluses of 5ml/kg plasmalyte will be given when: either map drops 20% from baseline or stroke volume drops 15% from baseline. if the patient is fluid responsive, a further 5ml/kg of fluid will be given. 3. vasopressor use: map (and stroke volume) becomes unresponsive to a fluid bolus then a bolus of phenylephrine or ephedrine may be given at the anesthesiologist's discretion.

Eligibility criteria:
inclusion criteria: * patients undergoing scoliosis repair * asa physical status classification system (asa) i-iii exclusion criteria: * pre-existing chronic kidney disease * oropharyngeal disease, e.g. pharyngitis * esophageal disease, e.g. heartburn, esophageal varices or hiatus hernia. * coagulopathy * scheduled for two stage procedures

Keywords: fluid therapy; transesophageal doppler
progesterone microspheres pharmacokinetic - pharmacodynamic (pk-pd) study

Conditions: Infertility

Summary: phase: i pharmacokinetic - pharmacodynamic (pk-pd) study. main objective: to establish the minimum effective dose of progesterone microspheres suspension, which administered by weekly intramuscular injection, will be able to induce transformation from a proliferative endometrium to a secretory endometrium. study design: randomized, controlled, open-label, parallel, dose-response clinical trial. sites: 1 subjects: 48 postmenopausal women.

sites: 1 phase: 1 main objective:to establish the minimum effective dose of progesterone microspheres suspension, which administered by weekly intramuscular injection, will be able to induce transformation from a proliferative endometrium to a secretory endometrium. secondary objectives: * to determine and compare the steady-state pharmacokinetic profile of investigational products. * to evaluate safety profile of investigational products in the study subjects. * to evaluate local tolerability of investigational products in the study subjects. study design:randomized, controlled, open-label, parallel, dose-response clinical trial. investigational products: * progesterone microspheres intramuscular injectable suspension 50 mg * progesterone microspheres intramuscular injectable suspension 100 mg * progesterone microspheres intramuscular injectable suspension 200 mg * progesterone microspheres intramuscular injectable suspension 300 mg study subjects: 48 healthy postmenopausal women, 45 - 60 years. brief description: after written informed consent, 48 eligible women will receive pretreatment with oral estradiol valerate, then, 14 days later, those with adequate endometrial thickness evaluated through ultrasound will be randomized to study treatments (one im injection each 7 days, for a total of 7 doses). 10 days after the first progesterone dose, an endometrial biopsy will be obtained. blood samples will be obtained for pharmacokinetic study.

Eligibility criteria:
inclusion criteria: * female * 45 to 60 years old * able to read and write * postmenopausal * body mass index equal or below 34.99 kg/m2 * healthy * normal uterus * time availability exclusion criteria: * hypersensitivity to progesterone or related compounds * hypersensitivity to estrogens * hysterectomy * history or present hormone-dependent tumor * history or present uterine cervix dysplasia * abnormal and clinically-significant laboratory test results * family history of breast cancer * history of thromboembolic disease * non-controlled hypertension * history of stroke * history of cardiac valve surgery * renal failure * hepatic failure * non-controlled diabetes * severe gastrointestinal disease * history of serious neurologic disease * reduced mobility * anemia * previous or concomitant hormonal therapy * previous or concomitant therapy with inhibitors or inductors of cytochrome

Keywords: progesterone microspheres postmenopausal luteal phase support
effect of low level laser therapy on prevention of radiotherapy induced xerostomia in cancer patients.

Conditions: Head and Neck Cancer

Summary: the purpose of the study is to evaluate the effectiveness of low level laser on radiotherapy induced xerostomia to improve oral function and decrease oral complication due to hyposalivation and thus enhancing survival.

in this part of the study, the materials and methods will be presented under the following headings: subjects, equipment, procedures of the study and the statistical procedures. 1. subjects: sixty patients who have head and neck cancer (oral cavity, pharynx, larynx, or occult primary tumor) submitted to conventional 3d radiotherapy, with irradiation fields necessarily encompassing all major salivary glands. the total dose ranged from 66 to 70 gy, given in fractions of 2 gy/day selected randomly from nuclear medicine department, oncology institute, mansoura university. these patients will be divided randomly into two groups of equal number, thirty patients for each group. group a: (laser group) this group of patients composes of thirty patients who will receive gaalas laser three times a week, on alternate day (48h interval) laser therapy will be initiated before the first radiotherapy session and ended after the last session, totaling 21 sessions (fernanda a. s.g. et al., 2016). group b :( control group) this group of patients composes of thirty patients will be treated with 15ml of a 2% citric acid solution applied as a mouth rinse for 30 sec (bozana loncar, d.m.d. et al., 2010) . the criteria of patients selection : 2. equipment used: 1-therapeutic equipment: laser therapy will be performed with an gaalas laser 2- evaluation tools: * unstimulated and stimulated saivery flow rate. * salivery immunoglobin a (siga) concentration in unstimulated saliva * the 11-item modified xerostomia inventory-dutch questionnaire version 22.

Eligibility criteria:
inclusion criteria: * - age range between 25-55 years. * all patients included in the study established hnc and will receive radiotherapy encompassing major salivary glands accompanied or not by surgery. * all patients enrolled to the study will have their informed consent. * both genders will participate in the study. * all the patients were examined medically by oncologist exclusion criteria: * - diabetes mellitus, * autoimmune diseases as sjorgen syndrome by established diagnosis criteria. * infectious diseases * collagen diseases, as were those with incipient tumors (stage t1 or t2) limited to the larynx, as well as those with trismus (reduced mouth opening capacity) due to surgical sequelae. * xerostomic drugs (antiretroviral medications, antihistamines, anticholinergics, antihypertensives, decongestants, narcotic analgesics, tricyclic antidepressants)

Keywords: low level laser xerostomia radiotherapy head and neck cancer
chronic abdominal pain after laparoscopic sleeve gastrectomy

Conditions: Obesity; Chronic Pain; Abdominal Pain

Summary: the study aims to evaluate the prevalence of postoperative chronic pain, defined as the persistence of abdominal pain for more than 3 months after laparoscopic sleeve gastrectomy.

the main goal of this study is to determine the incidence of chronic abdominal pain among patients who have undergone laparoscopic sleeve gastrectomy. patients who underwent this type of surgery at the department of general surgery and transplantology of the medical university of warsaw between january 2020 and august 2024 will be qualified for the study. the participants will be asked to complete an online questionnaire, including a pain scale and paindetect questionnaire.

Eligibility criteria:
inclusion criteria: * patients who underwent laparoscopic sleeve gastrectomy 3 months to 5 years earlier exclusion criteria: * lack of patient consent to participate in the survey * no possibility to contact the patient * revisional procedures

Keywords: laparoscopic sleeve gastrectomy chronic postoperative pain neuropathic pain
study tests the safety and effectiveness of su011248 in patients with non-small cell lung cancer having brain metastases

Conditions: Non-Small Cell Lung Cancer

Summary: this study will evaluate the safety, tolerability and efficacy of su011248 in patients with non-small cell lung cancer with brain metastases.


Eligibility criteria:
inclusion criteria: * patients with radiologically proven brain metastases secondary to non-small cell lung cancer * received previous whole brain radiation therapy and none, 1 or 2 prior systemic therapy for the treatment of advanced/metastatic non-small cell lung cancer exclusion criteria: * patients with brainstem lesions, spinal cord compression. carcinomatous meningitis, or leptomeningeal disease. * brain metastases \>4 cm in any linear direction * intracranial or intratumoral hemorrhage

Keywords: brain metastases sunitinib phase 2
evaluating airway sarcoidosis pathology with mri

Conditions: Sarcoidosis

Summary: sarcoidosis is a condition where inflamed cells clump together to form granulomas, which can lead to inflammation or scarring. it can affect any organ of the body, but most commonly affects the lungs. symptoms can be highly variable, and some patients have no symptoms where as others may develop fatigue or breathlessness. the causes of sarcoidosis are poorly understood. it commonly affects adults in their 30's or 40's. some patients present with symptoms suggestive of involvement in the airways, such as cough. inhalers containing steroid are commonly used, but there is a poor understanding of which patients may benefit. part of the problem is the lack of a sensitive way of measuring these effects and knowledge of how sarcoidosis affects the airways physiologically. the investigators would like to know more about the disease process of sarcoidosis, particularly where it involves the airways. this study will use a number of techniques in order to better understand to disease process. in order to assess whether sarcoidosis produces changes in airway ventilation (and whether these changes are stable or change over a short time period). this pilot study aims to recruit 6 patients who will have magnetic resonance imaging (mri) with inhaled xenon gas. during this technique, xenon and nitrogen mixture is inhaled and during a subsequent breath-hold, images of the lungs are taken. this creates a detailed view of the lung airway tree, to explore how the disease affects the airways and deeper lung tissue. this technique will be used alongside lung function tests, commonly performed in the laboratory setting and cardiopulmonary exercise testing, to see what happens in the lungs of this group of patients when they reach peak exercise capacity.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of sarcoidosis * sarcoidosis clinician diagnoses airways involvement * aged 18 and above exclusion criteria: * current combustible cigarette or electronic cigarette user * significant doubt over the diagnosis of sarcoidosis * asthma or other airways disease, requiring regular inhaler use * contraindication to mri identified on safety questionnaire * recent covid-19 infection (lateral flow or pcr swab positive within the last 28 days) or ongoing symptoms from covid-19
value eccentric and proprioception exercise into the injury effect in amateur football

Conditions: Hamstring Injury

Summary: this study evaluates the injury in amateur football, adding different excercise into the habitual practice. there are three groups, one of them do eccentric excercise, another group doing proprioception exercise and the last group don´t do any exercise.

there are three group with 10 participants each one. the group one will do hamstring eccentric exercise 12 series per 6 repeats. the group two will do three proprioception exercise 2 series per exercise and leg. and third group won't have add some exercise to their normal training. all participants will do the exercises during 12 weeks. before this 12 weeks they will be valuation with different tests, and this tests will have to repeat after this 12 weeks and 3 weeks after finish the exercises.

Eligibility criteria:
inclusion criteria: * training three times per week, add match day * more than two years of experience * not be injured * not having been operated on the lower extremity exclusion criteria: -
a full digital vs conventional protocol in management of zygomatico-maxillary complex fracture

Conditions: Zygomatic Fractures

Summary: this study aims to evaluate the accuracy of zygomatico- maxillary complex (zmc) fracture reduction and fixation using customized patient-specific implant and patient-specific predictive holes surgical guide versus conventional technique of reduction and fixation.

the zmc has multiple points of articulation with the craniofacial skeleton making accurate assessment of reduction at all articulations intraoperative in multiple planes very challenging and the interference of soft tissue edema and a narrowed visual field increases the possibility of intraoperative overcorrection or underestimation of pre-injured position of all fracture lines at the same time resulting in a suboptimal reduction. as a trial to maximize the benefits of digital planning carrying the plan into a real operating room using a patient-specific surgical guide to predrill screw holes and guide patient-specific implants during fixation according to the planning depend on ct scan.

Eligibility criteria:
inclusion criteria: * zygomatic fracture types iii, iv, v, vii, and viii according to rowe and killey's classification. * age range (18-60 years). * patients are willing for the surgical procedure and follow-up, with informed consent exclusion criteria: * zygomatic fracture type i, ii according to rowe and killey's classification. * patients with contraindications for general anesthesia. * patient on radiotherapy. * patients suffer from bone disease.

Keywords: zygomatic fracture computer guided surgery patient specific implant predictive holes surgical guide zygomatico-maxillary complex fracture
zd4054 (zibotentan) phase ii non-small cell lung cancer study

Conditions: Non Small Cell Lung Cancer; Lung Cancer

Summary: the aim of this study is to collect initial efficacy and safety data on the use of a new treatment zd4054 (zibotentan) when used in combination with pemetrexed (a standard chemotherapy agent) for the treatment of non-small cell lung cancer compared to treatment with pemetrexed alone


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed locally advanced or metastatic nsclc on entry into study suitable for pemetrexed therapy * patients that meet one of the following criteria: - progressed following one prior platinum-based chemotherapy regimen for locally advanced or metastatic disease; -progressed within 6 months of adjuvant platinum-based chemotherapy * life expectancy of \> 12 weeks exclusion criteria: * prior treatment with pemetrexed in the last 12 months. * prior therapy with an et receptor antagonist * any recent surgery, unhealed surgical incision, severe concomitant medical condition (eg, unstable cardiac, hepatic or renal disease) or significant laboratory finding which makes it undesirable for the patient to participate

Keywords: nsclc phase ii zd4054 pemetrexed lung cancer